Financial Performance - In 2022, the company's operating revenue reached CNY 13,808,761,327.75, an increase of 7.86% compared to CNY 12,802,015,553.25 in 2021[22]. - The net profit attributable to shareholders was CNY 464,359,718.95, representing a growth of 25.14% from CNY 371,083,746.30 in the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 230,751,956.99, up by 6.37% from CNY 216,930,409.23 in 2021[22]. - The net cash flow from operating activities was CNY 622,093,201.43, a significant recovery from a negative cash flow of CNY -162,437,381.47 in 2021[22]. - As of the end of 2022, the total assets amounted to CNY 13,435,980,913.62, reflecting a 4.62% increase from CNY 12,842,438,765.28 at the end of 2021[22]. - The net assets attributable to shareholders increased to CNY 4,331,072,648.54, a rise of 12.58% from CNY 3,847,233,622.82 in the previous year[22]. - The basic earnings per share increased to 0.19 yuan, up 26.67% from 0.15 yuan in 2021[23]. - The diluted earnings per share rose to 0.18 yuan, reflecting a 20.00% increase compared to the previous year[23]. - The gross profit margin for the main business was 24.56%, up 1.06 percentage points from the previous year[57]. - The overall gross profit margin for the company was 24.56%, which is close to the industry average[102]. Business Strategy and Operations - The company expanded its e-commerce business in the health product sector, leveraging existing resources to enhance market penetration[32]. - The company focused on optimizing product structure and expanding market share through new product introductions and enhanced customer services[33]. - The company emphasized the importance of strategic alliances with key customers to align with its development strategy[35]. - The establishment of a new subsidiary, Harbin Pharmaceutical Health Technology, focused on health products, aimed at rapid growth in online channels[35]. - The company has redefined its R&D strategy, focusing on digestive, respiratory, mineral, and chronic disease products, with an emphasis on rapidly developing health products as a key strategic initiative[36]. - The company operates seven core manufacturing bases to enhance its product and capacity advantages, optimizing the supply chain management to improve operational efficiency[37]. - The company has implemented cost control measures and lean management practices to improve its core competitiveness in product costs[37]. - The company is focusing on enhancing its R&D capabilities in biopharmaceuticals, with products including recombinant human erythropoietin injection and recombinant human granulocyte colony-stimulating factor injection[90]. - The company is committed to building a comprehensive product pipeline that spans prevention, treatment, recovery, and health maintenance[129]. Market and Industry Trends - In 2022, the pharmaceutical manufacturing industry reported revenues of CNY 2,911.14 billion, a year-on-year decrease of 1.6%, while operating costs increased by 7.8% to CNY 1,698.46 billion[38]. - The total profit for the pharmaceutical industry in 2022 was CNY 428.87 billion, reflecting a year-on-year decline of 31.8%[38]. - The new version of the medical insurance catalog includes 2,967 drugs, an increase of 107 from the previous version, indicating ongoing adjustments in the healthcare policy landscape[40]. - The health supplement industry in China is experiencing significant growth due to increased penetration and consumer stickiness, driven by policies such as the dual-track registration system for health foods[91]. - The pharmaceutical industry is facing challenges such as rising costs and intensified competition, with a projected average annual growth rate of over 8% in revenue and profit by 2025[126]. Risk Management and Compliance - There are no significant risks that could materially affect the company's operations during the reporting period[8]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[7]. - The company has a standard unqualified audit report issued by Beijing Xinghua Accounting Firm[4]. - The company is committed to building a robust compliance management system to mitigate risks while promoting product marketing and terminal market maintenance[133]. - The company anticipates facing policy risks in 2023, including potential price reductions due to centralized procurement and changes in medical insurance payment methods[136]. Governance and Management - The company has established a governance structure that ensures effective decision-making and risk management, protecting shareholder rights[139]. - The board of directors has improved its structure, ensuring independent oversight and compliance with legal requirements[140]. - The company has revised 24 internal regulations, including the Articles of Association and various meeting rules, to comply with legal and regulatory requirements[146]. - The company has established a dedicated board secretary to oversee information disclosure and ensure equal access to information for all shareholders[142]. - The company has implemented measures to enhance the confidentiality of insider information, ensuring compliance with relevant regulations[142]. Research and Development - Research and development expenses increased by 18.49% to 115.81 million RMB, driven by accelerated new product development[55]. - The company is actively involved in multiple R&D projects across various therapeutic areas, including digestive, respiratory, and chronic diseases[103]. - The R&D investment capitalized ratio was 29.11%, indicating a significant portion of R&D expenses is being recognized as intangible assets[111]. - The company has successfully passed the consistency evaluation for four products, which is expected to enhance market share and competitiveness[106]. Sales and Marketing - The company has recovered core store operation rights on various e-commerce platforms and fully launched self-operated stores across all channels, enhancing its e-commerce business[44]. - Membership marketing efforts have led to a membership base of 2.19 million, with member sales accounting for 73.85% of total sales[46]. - The company is focusing on online sales while gradually expanding offline distribution based on existing pharmacy channel capabilities[116]. - The company plans to enhance its digital marketing efforts, with a budget increase of 25% to improve customer engagement and retention[151]. Future Outlook - The company plans to achieve a revenue of 14.814 billion yuan in 2023, representing a year-on-year growth of 7.28%[131]. - The net profit, excluding non-recurring gains and losses, is expected to reach 320 million yuan, with a year-on-year increase of 15.85%[131]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 2 billion RMB for potential deals[158]. - Future outlook indicates a projected revenue growth of 20% for the upcoming fiscal year, driven by new product launches and market expansion strategies[151].

证券代码：600664 证券简称：哈药股份 哈药集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | □特定对象调研 □分析师会议 | | | 投资者关系 | □媒体采访 | √业绩说明会 | | 活动类别 | □新闻发布会 □路演活动 | | | | □其他 | （请文字说明其他活动内容） | | 活动参与人 员 | 线上黑龙江辖区上市公司 绩说明会的投资者 | 2022 年投资者 ...

2022 年第三季度报告 主要会计数据和财务指标 单位：元 币种：人民币 证券代码：600664 证券简称：哈药股份 哈药集团股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2、公司负责人林国人、主管会计工作负责人刘波及会计机构负责人（会计主管人员）刘波 保证季度报告中财务信息的真实、准确、完整。 3、第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 | --- | --- | --- | --- | --- | |-----------------------------------------------|-------------------|--------------------------------------|------------------|------------------------ ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 6,415,750,711.68, a slight increase of 0.16% compared to CNY 6,405,785,343.88 in the same period last year[21]. - The net profit attributable to shareholders of the listed company decreased by 64.33% to CNY 122,025,277.85 from CNY 342,088,698.57 year-on-year[21]. - The net profit after deducting non-recurring gains and losses was CNY 110,053,333.66, down 44.72% from CNY 199,077,310.22 in the previous year[21]. - The total revenue for the reporting period was CNY 6,415,750,711.68, a slight increase of 0.16% compared to the previous year, while operating costs decreased by 0.27% to CNY 4,912,718,059.43[65]. - The net profit for the first half of 2022 was CNY 146,663,962.57, down from CNY 365,615,681.29 in the same period of 2021, reflecting a decrease of approximately 60%[186]. - The total comprehensive income for the first half of 2022 was CNY 145,592,026.94, down from CNY 363,589,260.82 in the first half of 2021[194]. Cash Flow and Liquidity - The net cash flow from operating activities was CNY 165,171,692.83, an increase of 3.60% compared to CNY 159,437,052.40 in the same period last year[21]. - The company’s cash and cash equivalents increased by 33.24% to CNY 2,121,353,318.33, enhancing liquidity[65]. - The company reported a significant increase in cash flow from financing activities, indicating a stronger liquidity position moving forward[199]. - Cash inflow from financing activities reached $1,129,361,541.20, up from $863,205,638.57, with a net cash flow of $279,404,398.56 compared to a negative $53,029,020.84 last period[199]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 12,958,497,615.73, reflecting a 0.90% increase from CNY 12,842,438,765.28 at the end of the previous year[21]. - The total liabilities decreased slightly to CNY 8,373,836,303.86 from CNY 8,421,954,031.68, a reduction of about 0.6%[177]. - Current assets totaled CNY 8,968,958,540.13, up from CNY 8,733,006,005.16, indicating an increase of about 2.7%[175]. - The company reported a decrease in short-term borrowings to CNY 2,252,856,035.88 from CNY 2,077,702,561.19, indicating an increase of about 8.4%[175]. Research and Development - Research and development expenses increased by 24.72% to CNY 52,340,518.52, reflecting the company's commitment to enhancing its R&D capabilities[65]. - The company has over 20 product projects in the research phase, covering multiple therapeutic areas, with ongoing efforts to enhance the quality management system for drug development[50]. - The company has successfully completed the consistency evaluation for two products, with five additional products currently under review, indicating a proactive approach to regulatory compliance[50]. Market and Competitive Position - The pharmaceutical industrial sector faced challenges due to the impact of COVID-19, leading to a strategic adjustment in channel layout and product structure[23]. - The pharmaceutical commercial sector experienced a decline in sales revenue due to national cost control policies and the impact of repeated COVID-19 outbreaks in Heilongjiang province[23]. - The company aims to enhance its market competitiveness by leveraging its brand advantages and product resources, with 70 exclusive products and 280 products listed in the national medical insurance directory[39]. - The company is actively expanding new channels and increased market investment to enhance product competitiveness and terminal market maintenance[37]. Environmental Compliance and Social Responsibility - The company reported actual emissions of 0.815 mg/L for a major pollutant in the first half of 2022, which is below the permitted discharge limit of 12 mg/L[110]. - The company has conducted environmental risk assessments and established a comprehensive environmental risk prevention mechanism[120]. - The company has donated a total of 23.53 million yuan in charitable activities, benefiting over 470,000 individuals across eight provinces[125]. - The company is actively involved in poverty alleviation and rural revitalization efforts, guiding impoverished households to increase their income through agricultural projects[128]. Governance and Management - Key management changes included the resignation of four executives, including the former general manager, and the election of new members to the board of directors[94][99]. - The company reported a significant focus on strategic decision-making and governance, with the establishment of new committees to enhance oversight[95]. - The company emphasized the importance of compliance with legal and regulatory requirements in its governance practices[93].

Financial Performance - In 2021, the company reported a net profit of -130,174,518.92 CNY, resulting in a total distributable profit of -1,968,846,471.28 CNY, leading to no profit distribution for the year[7]. - The company did not extract statutory surplus reserves for the year, as the distributable profit was negative[7]. - The company achieved operating revenue of 12.80 billion RMB, an increase of 18.66% year-on-year[23]. - The net profit attributable to shareholders was 371.08 million RMB, a significant recovery from a loss of 1.08 billion RMB in the previous year[23]. - The net profit after deducting non-recurring gains and losses was 216.93 million RMB, compared to a loss of 714.94 million RMB in 2020[23]. - The weighted average return on equity increased to 10.13%, up 34.25 percentage points from -24.12% in 2020[24]. - The total assets at the end of 2021 were 12.84 billion RMB, reflecting an 8.40% increase from the previous year[23]. - The company reported a net cash flow from operating activities of -162.44 million RMB, an improvement from -728.15 million RMB in 2020[23]. - The basic earnings per share for 2021 was 0.15 RMB, recovering from -0.43 RMB in 2020[24]. - The company’s net assets attributable to shareholders increased by 10.56% to 3.85 billion RMB by the end of 2021[23]. Operational Highlights - The pharmaceutical industrial revenue was 3.46 billion RMB, while the pharmaceutical commercial revenue was 9.28 billion RMB[35]. - The company’s industrial segment saw a year-on-year sales volume increase of 26.2%, significantly boosting sales revenue[36]. - Gross profit margin improved by 7.26% compared to the same period last year, leading to a substantial increase in profitability for 2021[36]. - Non-recurring gains included compensation of 211.14 million yuan from the disposal of idle assets by a subsidiary[36]. - The company is focusing on product marketing by enhancing brand influence and expanding online sales channels, establishing long-term strategic partnerships with major e-commerce platforms[37]. - The company is advancing product development in key therapeutic areas such as neurology, oncology, pediatrics, and respiratory diseases, with several products passing consistency evaluations[39]. - The company has established seven core manufacturing bases to strengthen its product and capacity advantages, including antibiotic raw materials and formulations[39]. Market and Industry Trends - In 2021, the pharmaceutical manufacturing industry in China achieved a revenue of 2,928.85 billion yuan, with a year-on-year growth of 20.1%[40]. - The total profit of the pharmaceutical manufacturing industry reached 627.14 billion yuan, marking a year-on-year increase of 77.9%[40]. - The health supplement market is expanding rapidly, driven by consumer trends towards wellness, with the company leveraging its brand advantages to enhance product offerings[90]. - The new medical reform policies have led to the institutionalization of volume-based procurement, with the updated medical insurance catalog including 2,860 types of drugs[90]. - The pharmaceutical industry is expected to benefit from ongoing supply-side structural reforms, with companies possessing independent innovation capabilities positioned for competitive advantage[87]. Research and Development - Research and development expenses increased by 5.63% to 97.73 million RMB due to the rise in R&D projects[52]. - The company has established a key laboratory for traditional Chinese medicine quality research, enhancing its R&D capabilities[51]. - The company holds 1,804 drug approvals and 86 health product approvals, with 69 exclusive drugs[51]. - R&D investment amounted to 147 million RMB, an increase of 19.17% year-on-year, representing 1.15% of total revenue and 4.23% of the pharmaceutical industry revenue[76]. - The company’s R&D projects are at various stages, with some still in the early research phase, leading to lower overall R&D spending compared to competitors[111]. Risk Management - There were no significant risks that materially affected the company's operations during the reporting period[9]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[8]. - The company focuses on compliance and risk prevention to ensure stable and high-quality development amidst regulatory pressures and market competition[47]. - The company acknowledges R&D risks due to high investment, long cycles, and low success rates in the pharmaceutical industry[133]. - The company is exposed to raw material procurement risks, with rising costs influenced by macroeconomic factors and international energy prices[133]. Corporate Governance - The company maintains full independence in operations, assets, and finances, with no reliance on the controlling shareholder[141]. - Independent directors account for over one-third of the board, enhancing decision-making processes[141]. - The company has established four specialized committees to strengthen board governance and ensure healthy development[141]. - The company has implemented strict confidentiality measures regarding insider information, with no leakage incidents reported[141]. - The company has successfully conducted multiple shareholder meetings, with all resolutions passed in compliance with legal and regulatory requirements[144]. Employee and Management Compensation - The total pre-tax remuneration for the entire management team during the reporting period was 2,101,670 RMB[153]. - The company has implemented a market-oriented compensation system for employees and senior management, emphasizing performance-based incentives and strict control of labor costs[181]. - The company has conducted two meetings of the remuneration and assessment committee, focusing on the review of incentive plans and performance management[181]. - The company’s board of directors has approved the stock option and restricted stock incentive plan for 2021[181]. - The total number of shares held by the management team at the beginning of the year was 505,500 shares, and at the end of the year, it was 4,855,500 shares, reflecting a significant increase[153].

证券代码:600664 证券简称:哈药股份 编号:临 2022-036 哈药集团股份有限公司 关于参加"2022 年投资者网上集体接待日 活动暨业绩说明会"的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担个别及连带责任。 为促进上市公司规范运作、健康发展，增强上市公司信息透明度，加强与广大 投资者沟通交流，进一步提升投资者关系管理水平，黑龙江省上市公司协会联合深 圳市全景网络有限公司，将于 2022 年 5 月 12 日 14:30-16:30 在"全景路演" （https://rs.p5w.net/html/132395.shtml）举办"黑龙江省上市公司 2022 年投 资者网上集体接待日活动暨业绩说明会"。 出席本次活动人员有：公司总经理、财务负责人、董事会秘书。（如遇特殊情 况，参与人员可能会有调整，公司不再另行公告。） 为充分尊重投资者、提升交流的针对性，现就公司本次活动提前向投资者公开 征集问题，广泛听取投资者的意见和建议。投资者可于2022年5 月12 日12:00 前 访问 https://ir.p5w.net/zj ...

Financial Performance - The company's operating revenue for Q1 2022 was ¥3,333,837,987.01, representing an increase of 11.88% compared to the same period last year [6] - The net profit attributable to shareholders of the listed company was ¥100,446,359.10, reflecting a growth of 21.21% year-on-year [6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥96,805,205.77, which is an increase of 88.58% compared to the previous year [6] - The basic earnings per share for the period was ¥0.04, up by 33.33% year-on-year [6] - Operating profit for Q1 2022 was CNY 160,484,032.82, up 20.6% from CNY 133,031,105.84 in Q1 2021 [31] - The total cost of operations for Q1 2022 was CNY 3,175,613,101.54, an increase of 10.4% from CNY 2,878,452,857.75 in Q1 2021 [28] - The total comprehensive income attributable to the parent company's owners for Q1 2022 was ¥100,715,949.51, compared to ¥82,744,240.91 in Q1 2021, representing an increase of approximately 21.5% [33] Assets and Liabilities - The total assets at the end of the reporting period were ¥12,764,203,877.95, a decrease of 0.61% from the end of the previous year [8] - Total liabilities decreased to CNY 8,233,515,215.76 from CNY 8,421,954,031.68, a reduction of approximately 2.2% [28] - Total equity increased to CNY 4,530,688,662.19 from CNY 4,420,484,733.60, reflecting a growth of about 2.5% [28] - The company's total assets amounted to CNY 12,764,203,877.95, a slight decrease from CNY 12,842,438,765.28 [28] Cash Flow - The net cash flow from operating activities was ¥154,882,854.26, with a year-on-year comparison deemed not applicable [6] - Cash inflow from operating activities totaled ¥3,277,424,882.21 in Q1 2022, compared to ¥3,050,042,798.87 in Q1 2021, reflecting an increase of about 7.4% [33] - The net cash flow from operating activities for Q1 2022 was ¥154,882,854.26, a significant improvement from a net outflow of ¥173,741,428.63 in Q1 2021 [33] - Cash inflow from investment activities was ¥43,844,524.34 in Q1 2022, compared to ¥1,585,891.74 in Q1 2021, showing a substantial increase [34] - The net cash flow from investment activities for Q1 2022 was ¥11,988,054.23, recovering from a net outflow of ¥13,774,017.34 in Q1 2021 [34] - Cash inflow from financing activities in Q1 2022 was ¥583,415,780.00, down from ¥810,974,027.78 in Q1 2021, indicating a decrease of approximately 28.0% [34] - The net cash flow from financing activities for Q1 2022 was -¥5,098,076.67, compared to a positive net flow of ¥65,951,861.77 in Q1 2021 [34] - The ending balance of cash and cash equivalents as of Q1 2022 was ¥1,753,711,206.00, up from ¥775,151,835.18 at the end of Q1 2021, representing an increase of approximately 126.5% [34] Shareholder Information - Total number of common shareholders at the end of the reporting period is 112,222, with the largest shareholder, Harbin Pharmaceutical Group Co., Ltd., holding 1,173,237,023 shares, accounting for 46.56% [16] - The largest shareholder, Harbin Pharmaceutical Group Co., Ltd., has pledged 926,857,248 shares [16] - There are no known related party transactions among the top shareholders [18] Research and Development - Research and development expenses for Q1 2022 were CNY 24,582,703.64, an increase of 9.7% compared to CNY 22,420,110.21 in Q1 2021 [29] Inventory and Receivables - The company experienced a decrease in other receivables by 44.04%, primarily due to repayments received [12] - Accounts receivable reached ¥4,199,524,541.69, up from ¥3,954,581,442.97 year-over-year, indicating a growth of approximately 6.2% [19] - Inventory decreased to ¥1,753,680,748.74 from ¥2,063,793,602.49, reflecting a reduction of about 15% [23] Other Information - The company has not disclosed any significant new product developments or market expansion strategies in the current report [18] - The company reported a decrease in other comprehensive income, with a net amount of CNY 269,590.41 compared to a loss of CNY 125,541.80 in Q1 2021 [31] - The company maintained a stable level of long-term borrowings at CNY 34,306,712.35, showing a minor increase from CNY 34,086,428.35 [28] - The company reported a significant decrease in cash outflow for employee payments, which was ¥394,603,625.37 in Q1 2022, down from ¥499,184,526.40 in Q1 2021, a reduction of about 20.9% [33]

2021 年年度报告 公司代码：600664 公司简称：哈药股份 哈药集团股份有限公司 2021 年年度报告 1 / 242 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 北京兴华会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人徐海瑛、主管会计工作负责人刘波及会计机构负责人（会计主管人员）刘波声明： 保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经北京兴华会计师事务所有限公司审计，公司2021年度母公司实现净利润-130,174,518.92元 ，依照《公司法》和《公司章程》规定本年未提取法定盈余公积，加上年初未分配利润- 1,838,671,952.36元，2021年可供分配利润为-1,968,846,471.28元，因公司本年度可分配利润为 负，所以本年度公司不实施利润分配，也不进行资本公积金转增股本。 六、 前瞻性陈 ...

2021 年第三季度报告 单位：元 币种：人民币 证券代码：600664 证券简称：哈药股份 哈药集团股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期 年初至报告期 | --- | --- | --- | --- | --- | |------------------------------------------------|------------------|------------------------------|------------------|------------------------- ...

Financial Performance - The company's operating revenue for the first half of 2021 reached ¥6,405,785,343.88, representing a 33.19% increase compared to ¥4,809,380,177.49 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was ¥342,088,698.57, a significant recovery from a loss of ¥333,302,234.51 in the previous year[23]. - The net cash flow from operating activities was ¥159,437,052.40, improving from a negative cash flow of ¥166,711,071.07 in the same period last year[23]. - The basic earnings per share for the first half of 2021 was ¥0.14, recovering from a loss of ¥0.13 in the same period last year[24]. - The weighted average return on net assets was 9.42%, a recovery from -7.56% in the previous year[24]. - The net profit for the first half of 2021 was ¥365,615,681.29, a significant recovery from a net loss of ¥312,721,712.23 in the first half of 2020[150]. - The total comprehensive income attributable to the parent company for the first half of 2021 was CNY 340,062,278.10, compared to a loss of CNY 1,045,344,052.21 in the first half of 2020[152]. Revenue and Cost Analysis - The company's operating costs increased by 30.33% to ¥4,926,062,404.91 from ¥3,779,564,910.36 year-on-year, driven by increased sales volume[55]. - The total operating costs amounted to ¥6,078,569,019.92, up from ¥4,957,933,116.16, reflecting a growth of 22.6%[146]. - Sales expenses rose significantly by 49.11% to ¥595,312,026.87, attributed to higher promotional costs for market expansion[55]. Asset and Liability Overview - The total assets of the company at the end of the reporting period were ¥12,041,241,934.00, a 1.64% increase from ¥11,847,534,453.08 at the end of the previous year[23]. - The company's cash and cash equivalents at the end of the period amounted to ¥1,055,709,720.44, representing 8.77% of total assets, an increase of 17.69% from the previous year[58]. - The total liabilities rose to ¥5,684,499,053.51, up from ¥5,611,171,009.10, indicating a growth of 1.3%[146]. - The company's total liabilities decreased to CNY 7,743,816,564.78 from CNY 7,858,964,273.05, a decline of about 1.46%[139]. Research and Development - The company has 20 product projects in the research stage, with 4 new product projects initiated during the reporting period[47]. - Research and development expenses for the first half of 2021 were ¥41,965,014.24, down from ¥54,154,695.03 in the same period last year, a decrease of 22.5%[150]. - The company is developing 3 health products in its newly established health research institute, achieving preliminary progress[47]. Market Position and Strategy - The company focused on target management and enhanced team specialization, leading to significant sales revenue growth in the reporting period[25]. - The company is focused on leveraging its brand and product advantages to enhance market competitiveness and drive growth[39]. - The company actively expanded new sales channels and optimized management processes to improve operational efficiency during the pandemic[35]. Environmental and Social Responsibility - The company has implemented pollution prevention facilities, including wastewater treatment systems with a design capacity of 20,000 tons per day at the main plant[84]. - The company donated calcium supplements valued at 16.034 million yuan to support health initiatives for disadvantaged groups[96]. - The company is actively involved in poverty alleviation and rural revitalization efforts, aligning with national strategies[96]. Corporate Governance and Management Changes - The company has undergone significant management changes, with new appointments in key positions, including the election of a new chairman and several directors[72]. - The company appointed new executives, including Liang Chen, Wang Penghao, Wang Haisheng, and Lu Chuanyou as vice presidents[75]. - The company’s independent directors and board members were elected during the first extraordinary shareholders' meeting of 2021[75]. Future Outlook - The company plans to introduce several new products and enhance its product pipeline, with multiple projects expected to reach milestone stages in the second half of the year[52]. - The company plans to continue focusing on market expansion and new product development to sustain growth momentum in the upcoming quarters[150].